Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1Holistic ...
H. Lundbeck A/S (Lundbeck) today announced results from a long-term follow-up in patients who have received bexicaserin (LP352) for up to two years. Bexicaserin is a novel, investigational drug for ...
A new study led by researchers from the Institute of Atmospheric Physics of the Chinese Academy of Sciences (CAS) has ...
Zurich, Switzerland, December 03, 2025 - MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive ...
Danica Patrick spent her entire racing career living through the pressures most people will never come close to facing. And to stay optimistic and positive in her life, she has developed a set of ...